Eli Lilly and Co. (NYSE: LLY) has secured a $625 million contract modification to supply 500,000 more doses of the company’s COVID-19 monoclonal antibody drug to the U.S. Army. Army Contracting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback